*All times are shown in EDT

8:00 am Breakfast Briefing: NSCLC – An Overview of the Landscape


  • A top level view of the NSCLC landscape from the preclinical to approved therapies
  • Emerging trends in technologies, combinations, and other innovative treatment strategies
  • The challenges and future of NSCLC treatment

8:20 am Opening Remarks from Chairperson

  • Mike Humphries US Scientific Director- Lung Cancer , Takeda Oncology

Recent Advancements in Targeted Therapy and Immunotherapy in the Treatment of Advanced NSCLC

8:30 am Data & Development Plans With SAR444245 (THOR-707): A Non-Alpha IL-2

  • Giovanni Abbadessa Global Head of Oncology Early Development, & Global Project Head, peg-IL-2 (THOR-707 / SAR444245), Sanofi Genzyme

8:50 am Panel Discussion: Addressing the Shortcomings of Developing NSCLC-Targeted Therapies

  • Robert Doebele Chief Scientific Officer , Rain Therapeutics
  • Giovanni Abbadessa Global Head of Oncology Early Development, & Global Project Head, peg-IL-2 (THOR-707 / SAR444245), Sanofi Genzyme


  • Patient population response differences and how to overcome these
  • What design elements are most optimal to achieve clinical benefit?
  • The push to early disease: what will this entail?
  • How can the mechanism of action be predicted for each patient and thus inform dosing strategies?

Generations of Progress in Targeting EGFR Through TKIs

9:10 am The Osimertinib Story – Innovating & Learning from Every Chapter to Beat T790M Resistance & Advance into Early EGFRm Disease

  • Serban Ghiorghiu Head of Clinical, Late Development Oncology R&D , AstraZeneca & European Commission’s Mission for Cancer, Board Member


  • Chapter 1 – Delivering one of the fastest-ever development programmes: Tackling T790M driven resistance through novel chemistry; creating innovative study designs focused on patient selection, selecting the right dose, driving seamless worldwide trials and registration strategies; and acting fast on what we learned from the data to rapidly expand into first-line and adjuvant settings.
  • Chapter 2 – Today’s focus: Building on yesterday’s foundations to extend osimertinib into early disease to improve patient outcomes.
  • Chapter 3 – Looking ahead, the future focus takes osimertinib a step beyond into more lines of treatment: going further into earlier disease settings; addressing locally advanced, unresectable disease; and unlocking potential for combination opportunities that could be the key to targeting resistance mechanisms

9:40 am Addressing EGFR Mutation-Driven Resistance Using Next-Generation EGFR Inhibitors

  • Mark Petronczki Head of Cancer Pharmacology and Disease Positioning, Boehringer Ingelheim RCV GmbH & Co KG


• EGFR resistance mutations limit the clinical impact of approved tyrosine kinase inhibitors in EGFR-mutated NSCLC
• Discovery and characterization of EGFR wild-type sparing inhibitors with potent activity against the two major EGFR resistance mutations T790M and C797S
• Next generation EGFR inhibitors prevent and tackle resistance mutations arising upon treatment with approved EGFR inhibitors

10:10 am Virtual speed networking break


Grab a quick cup of tea or coffee from the comfort of your own home office and jump straight into the speed networking session. This is your opportunity to connect with new contacts from active companies in the field and exchange digital business cards. Network and form lasting connections through this exclusive virtual speed networking!

Targeting Mutation and Overexpression in EGFR

11:00 am Efficacy and Safety of Mobocertinib in NSCLC Patients with EGFR Exon 20 Insertions

  • Mike Humphries US Scientific Director- Lung Cancer , Takeda Oncology


  • Overview of EGFR exon20 insertions in NSCLC and how they differ from common sensitizing EGFR mutations
  • Current challenges associated with targeting these alterations and theneed for effective therapies
  • Preclinical and clinical profile of Mobocertinib

11:30 am Discovery and Early Clinical Development of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 Insertion Mutations

  • Leigh Zawel Chief Scientific Officer/Executive Partner, Cullinan Oncology/MPM Capital


  • Challenges in the discovery of an Ex20 targeted therapy
  • Preclinical characterization of CLN-081 in models of Ex20 NSCLC
  • Safety and early signs of efficacy in patients with Ex20 NSCLC

12:00 pm BDTX-189: A MasterKey Inhibitor of EGFR and HER2 Exon 20 Insertion Mutations and Allosteric HER2 Mutations


• The role of Black Diamond’s proprietary MAP platform for the identification and validation of allosteric EGFR and HER2 oncogenic driver mutations, including Exon 20 insertion mutations
• Overview of the profile of BDTX-189, including a presentation of preclinical pharmacokinetic, safety, and anti-tumor activity data
• The ongoing MasterKey-01 trial, a Phase 1/2 clinical trial designed to evaluate BDTX-189 for the treatment of patients with solid tumors with a range of allosteric EGFR and HER2 mutations

12:30 pm The True Value of Research

  • Jill Feldman Lung Cancer Patient and Advocate, Co-Founder, EGFR Resisters


The true value of research to patients and our families is Hope and that’s what drug development provides – a chance and that’s hope!

12:45 pm Online Networking Lunch

Molecular Diagnostics To Enable Patient Selection & Advance Targeted Drug Candidates

1:30 pm Informed By The Tumor: The Power of a Personalized ctDNA Assay For MRD Detection & Monitoring in NSCLC

  • Olga Alexeeva Senior Manager - Marketing, Business Development & New Strategic Launches, Natera
  • John Simmons Global Vice President, Biopharma Business Development, Natera
  • Angel Rodriguez Oncology Medical Director, Natera


• Latest clinical data from 2021 publications and presentations
• Advantages of a personalized, tumor-informed ctDNA assay for molecular residual disease detection
• Applications of Signatera in clinical trial design to maximize trial success, and accelerate time to data readout

2:00 pm Advancing Biomarker Discovery: Enabling improved tumor immunogenomics through a comprehensive approach


  • Predicting patient response to immunotherapies requires a robust and comprehensive approach to tumor immunogenomics.
  • By combining highly sensitive, exome-scale DNA and RNA sequencing with advanced analytics, ImmunoID NeXT™ provides a broad view of the tumor and the immune-related components of the tumor microenvironment from a single, limited sample.
  • Combination of ImmunoID NeXT and our exome-wide liquid biopsy assay, NeXT Liquid Biopsy, allows for increased exploration of critical areas of tumor biology.

Targeting the MET Oncogene in NSCLC

2:20 pm Preclinical Evaluation of MCLA-129: A Bispecific Antibody Targeting c-MET and EGFR


  • Functional screening antibody panel
  • Inhibition of signaling
  • Fc mediated MOA

Targeting PI3K and Associated Pathways to Address Resistance

2:50 pm Targeting PI3K and Associated Pathways to Address Resistance

  • Harish Dave Co-Founder & Chief Medical Officer , AUM Biosciences

3:20 pm Networking Break

Drugging the Undruggable KRAS Mutation in NSCLC

3:50 pm Targeting KRAS Mutant Non Small Cell Lung Cancer with Adagrasib: Current Status and Future Questions


  • History of targeting KRAS in the clinic and recent advancements to directly target KRAS G12C
  • Clinical progress of KRAS G12C inhibitors (e.g. adagrasib) and treatment of patients with NSCLC
  • Future questions and directions for targeting KRAS G12C, including biomarkers and combination strategies

4:20 pm Mechanisms of Resistance to KRAS G12C Inhibitors

  • Chiara Ambrogio Assistant Professor of Molecular Biology , University of Turin


  • Are there any genetic determinants for resistance to KRAS inhibitors?
  • Can we identify biomarkers to predict the response to KRAS inhibitors?
  • Is KRAS degradation a valuable strategy to overcome drug resistance?

4:50 pm Mechanisms of Resistance to KRAS G12C Inhibition

  • Ryan B. Corcoran Director, Gastrointestinal Cancer Center Program, Scientific Director , Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, Associate Professor of Medicine, Harvard Medical School

5:20 pm Unique Dual RAF/MEK Inhibitor VS-6766 for KRAS Mutant NSCLC


• Combination of VS-6766 with FAK inhibitor for KRAS G12V mt NSCLC – preclinical rationale
• Combination of VS-6766 with FAK inhibitor for KRAS G12V mt NSCLC – clinical data
• Combination of VS-6766 with a G12C inhibitor for KRAS G12C mt NSCLC

5:50 pm Closing Remarks from the Chair

  • Trever Bivona Professor of Medicine & Cellular and Molecular Pharmacology, UCSF

6:00 pm End of day